Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Amikacin for Gram-Negative Ventilator-Associated Pneumonia
NCT02574130Completed
- Sponsor
- Thammasat University
- Start
- Jul 2015
- Primary completion
- Apr 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of amikacin liposome inhalation suspension in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Thammasat University. Primary endpoint: Cure rate. Started Jul 2015; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT02574130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574130.